Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Adams Harkness Cuts MedImmune to 'Market Perform'

Adams Harkness downgraded MedImmune (MEDI) to market perform.

Analyst Felicia Reed says as expected, the FDA approved MedImmune's FluMist intranasal flu vaccine for healthy people aged 5-50, putting it on track for a third-quarter launch. She expects FluMist sales to accelerate the slowing growth rate currently driven by MedImmune's Synagis drug.

However, Reed thinks FluMist sales will be lackluster until the populations most likely to benefit -- children under 5, high-risk adults and kids, and the elderly -- are included on the label. Moreover, she doesn't foresee additional catalysts that will drive the stock higher in the next six months.

blog comments powered by Disqus